Galapagos (NASDAQ:GLPG) 株価情報

Galapagos

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.

Galapagos NV - American Depositary Shares

Galapagos NV

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) with a Buy and maintains $11 price target.

News

Price Target

Reiteration

Analyst Ratings

CDXC

HC Wainwright & Co. Reiterates Buy on ChromaDex, Maintains $11 Price Target

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and maintains $230 price target.

Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Maintains $230 Price Target

Telsey Advisory Group analyst Cristina Fernandez maintains Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Market Perform and maintains $80 price target.

Telsey Advisory Group Maintains Market Perform on Nike, Maintains $80 Price Target

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) with a Buy and maintains $8 price target.

GANX

HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target

Telsey Advisory Group analyst Cristina Fernandez maintains Academy Sports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) with a Outperform and maintains $60 price target.

Telsey Advisory Group Maintains Outperform on Academy Sports, Maintains $60 Price Target

On Monday, Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFAI#NASDAQ">FFAI</a>) unveiled its AI strategy, products, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44349861/faraday-future-establishes-the-worlds-first-ai-hybrid-extended-range-electric-powertrain-system-co" rel="noreferrer noopener">and technology at its first Open AI Day</a>.
The company also announced the launch of Future AIHER, the world's first AI hybrid extended-range electric powertrain system company. AIHER will focus on developing a super AI hybrid extended-range system and a super AI extended-range system, along with supporting powertrain solutions.
Future AIHER aims to commercialize AI-driven range extender systems for Extended Range Electric Vehicles (EREVs), blending hybrid and range-extender technologies.
Its applications extend beyond cars to EVTOL aircraft, commercial trucks, and electric boats.
FF and FX may offer up to three powertrain options: battery electric, range-extended, and a super AI hybrid extended-range system tailored for U.S. consumers.
FF aims to fast-track the launch of three key AI-powered products for potential future FX mass-production models: the Super AIHER system, an AI Cabin Agent, and an end-to-end open-source large-model AI driving system.
YT Jia, Founder and Chief Product and User Ecosystem Officer of FF said, &nbsp;&#8220;AI will reshape the use of automobiles. When we defined the FF 91, AI was nowhere near the capabilities of today, but we were envisioning a growing technology which let the car learn how the individual user prefers to use all functionality of the vehicle by itself. The way people move is a core use case for AI applications, and its future is being completely restructured.&#8221;
Last week, the company disclosed its entry into the New York State EV market with the launch of the FF 91 2.0,&nbsp;followed by <a target="_blank" href="https://www.benzinga.com/25/03/44242667/faraday-future-forays-into-new-york-ev-market-with-ff-91-20-launch" rel="noreferrer noopener">potential future FX models</a>.
On March 10, the company officially changed its ticker symbol for its class&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44184554/faraday-future-announces-new-ticker-symbol-ffai" rel="noreferrer noopener">A common stock from "FFIE" to "FFAI"</a>.
Price Action: FFAI shares closed higher by 5.69% at $1.30 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44347886/consumer-tech-news-mar-10-mar-14-manus-ai-creating-hype-tesla-eyes-affordable-version-model-y-in-china-more" target="_blank" rel="noreferrer noopener">Consumer Tech News (Mar 10-Mar 14): Manus AI Creating Hype, Tesla Eyes Affordable Version Model Y In China &amp; More</a></li>
</ul>
Image via Shutterstock.

Equities

Small Cap

FFAI

FF Open AI Day: Faraday Future Launches AIHER, Aims To Revolutionize EV And Hybrid Powertrains

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth initiates coverage on Actuate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTU#NASDAQ">ACTU</a>) with a Buy rating and announces Price Target of $20.

Initiation

ACTU

HC Wainwright & Co. Initiates Coverage On Actuate Therapeutics with Buy Rating, Announces Price Target of $20

HC Wainwright &amp; Co. analyst Oren Livnat reiterates ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) with a Buy and maintains $94 price target.

ANIP

HC Wainwright & Co. Reiterates Buy on ANI Pharmaceuticals, Maintains $94 Price Target

B of A Securities analyst Ebrahim Poonawala maintains U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) with a Buy and lowers the price target from $50 to $49.

B of A Securities Maintains Buy on U.S. Bancorp, Lowers Price Target to $49

FLAMINGO-01 Data Safety Monitoring Board (DSMB)
The FLAMINGO-01 DSMB met twice in 2024, most recently in December 2024, and recommended to continue the study as is without modification. No serious adverse events related to GLSI-100 have been reported to date in FLAMINGO-01. Additional safety updates and comparison to the Phase IIb safety data are provided below.
Phase IIb Safety Data
In the prospective, randomized, single-blinded, placebo-controlled, multi-center (16 sites led by&nbsp;MD Anderson Cancer Center) Phase IIb clinical trial of HLA-A&#x2A;02 breast cancer patients, 46&nbsp;HER2/neu&nbsp;3+ over-expressor patients were treated with GLSI-100, and 50 placebo patients were&nbsp;treated with GM-CSF alone. After 5 years of follow-up, there was an 80% or greater reduction in&nbsp;cancer recurrences in the HER2/neu&nbsp;3+ patients who were treated with GLSI-100, followed, and&nbsp;remained disease free over the first 6 months, which we believe is the time required to reach peak immunity and thus maximum efficacy and protection. The Phase IIb results can be summarized as follows:
<ul>
<li>80% or greater reduction in metastatic breast cancer recurrence rate over 5 years of follow-up compared to 20-50% reduction in recurrence rate by other approved products</li>
<li>Peak immune response at 6 months</li>
<li>No reported serious adverse events attributable to treatment</li>
<li>Well-tolerated safety profile</li>
</ul>
Full immunization was received in the Primary Immunization Series (PIS), which included the first 6 GLSI-100 injections over the first 6 months.&nbsp;The PIS elicited a potent immune response as measured by local skin tests and immunological assays. Further, booster injections given every 6 months prolonged the immune response, thereby providing longer-term protection. In the Phase IIb and three Phase I clinical trials,&nbsp;where 146 patients were treated,&nbsp;the GP2 immunotherapy was well tolerated, and there were no reported serious adverse events related to GLSI-100.
The Phase IIb safety data was published at ASCO in 2021 with the following findings:
<ul>
<li>GP2 immunotherapy is well-tolerated and no safety signal for GP2 was identified. Additionally, no serious adverse events related to GP2 immunotherapy were reported over the full 5 year treatment and follow-up periods. &nbsp;</li>
<li>The majority of patients experienced mild or moderate injection site reactions, which accounted for approximately 70% of reported adverse events. &nbsp;</li>
<li>The incidence of adverse events was similar across HER2 3+ and HER2 1-2+ breast cancer patients, consistent with the previously reported findings that the immune response was similar across both patient populations. This suggests that GP2 immunotherapy could be a potential treatment in HER2 1-2+ patients or in other HER2 expressing cancers. &nbsp;</li>
</ul>
FLAMINGO-01 Safety Data
Analysis of the open label data from FLAMINGO-01 has commenced and has been conducted in a manner that maintains the study blind. The open label safety data is based on the patients enrolled to date in FLAMINGO-01 and is thus preliminary. While comparing this preliminary FLAMINGO-01 data to the Phase IIb clinical trial data is possible, these preliminary results from FLAMINGO-01 are not a prediction of future results. It is important to note that this preliminary summary may not reflect results at the end of the study.
A preliminary review of FLAMINGO-01 safety data in both the HLA-A&#x2A;02 treated and placebo arms and the third open label arm with all other HLA types, shows that GP2 immunotherapy continues to be well-tolerated and that no safety signal for GP2 has yet to be identified across all arms of the study. Like the Phase IIb clinical trial, the most frequent adverse event is injection site reaction, which is also a sign of an immune response. As the study matures, the frequency of events related to GLSI-100 will increase, which based on the current data, suggests that the FLAMINGO-01 safety data is trending towards a similar safety profile to that of the Phase IIb study. As a result, this preliminary analysis, and that of the DSMB, is to recommend no changes to FLAMINGO-01 nor to the investigator brochure, where any new or unexpected safety data might be added.
CEO Snehal Patel commented, "We are pleased that the preliminary safety data from FLAMINGO-01 is consistent with the Phase IIb safety data suggesting that GLSI-100 is well tolerated with no safety signal. The safety data, especially the diameter of injection site reactions, can be measured and thus can be used to assess the magnitude of immune response, along with our GP2 skin test. We look forward to analyzing the immune response data and comparing FLAMINGO-01 preliminary results to the Phase IIb data. There is also the potential that some of the HLA, safety, or immune response data from FLAMINGO-01 will be presented at future scientific conferences as the data continues to mature and patient enrollment continues to accelerate."

Biotech

Health Care

General

GLSI

Greenwich LifeSciences Announced An Update On FLAMINGO-01 Open Label Safety Data

HC Wainwright &amp; Co. analyst Scott Buck reiterates Veritone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) with a Buy and maintains $6 price target.

VERI

HC Wainwright & Co. Reiterates Buy on Veritone, Maintains $6 Price Target

DuPont intends to appoint a Chief Financial Officer for the future Electronics company who will be an external hire with a proven track record of performance at a publicly traded company.
 &nbsp;

Management

DuPont Names Jon Kemp To Be The CEO And Board Member For Future Independent Electronics Public Company

HC Wainwright &amp; Co. analyst Kevin Dede reiterates Bit Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) with a Buy and maintains $7 price target.

BTBT

HC Wainwright & Co. Reiterates Buy on Bit Digital, Maintains $7 Price Target

On Monday, the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for Monogram Technologies Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRM#NASDAQ">MGRM</a>) Monogram <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">mBôs TKA System</a>.
Ben Sexson, Monogram&#8217;s Chief Executive Officer, commented, &#8220;We are particularly excited about the system&#8217;s performance and its potential to advance robotics in orthopedic medicine. We believe we will have strong product-market fit and are well-positioned to make a meaningful impact.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44338422/hasbro-focuses-on-adult-toy-market-amid-declining-toy-sales-report" rel="noreferrer noopener">Hasbro Focuses On Adult Toy Market Amid Declining Sales: Report</a>
Monogram Tech may Market the Monogram mBôs TKA System subject to the Federal Food, Drug, and Cosmetic Act requirements.
The Monogram mBôs TKA System is designed to deliver robotic-assisted total knee arthroplasty.
Monogram believes in the benefits of personalized robotic surgery, enabled by patient-specific imaging (CT-based) and accurate predictive navigation tools. The company sees an opportunity to be part of the ongoing adoption of robotic-assisted procedures.
The company is focused on initial placements with key surgeon KOLs in strategic geographies to establish clinical experience and demonstrate the system&#8217;s advantages in real-world surgical settings.
Upcoming Milestones include:
<ul>
<li>Upgrade cleared system cutting system and other improvements to enhance competitiveness.</li>
<li>Continues to refine and enhance its next-generation technology in parallel with regulatory and clinical trial preparations to improve future competitiveness and expand to new applications.</li>
<li>The company is working to obtain regulatory clearance to initiate clinical trials in India in collaboration with its strategic partner, Shalby Limited, <a href="https://www.benzinga.com/pressreleases/25/02/ac43971740/monogram-technologies-provides-regulatory-update-on-mb-s-tka-system-and-clinical-trial-preparatio" target="_blank" rel="noreferrer noopener">a hospital chain</a>.</li>
<li>The company is working to advance the submission of additional clinical applications to expand the robotic system&#8217;s capabilities and establish it as a versatile, multi-application platform.</li>
</ul>
Cash and cash equivalents totaled $15.7 million as of December 31, 2024. The company continues to direct its resources, focusing on commercializing the mBôs TKA System as <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/ac44292476/correction-monogram-technologies-reports-full-year-2024-financial-results" rel="noreferrer noopener">capital efficiently as possible</a>.
Price Action: MGRM stock closed at $2.33 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/03/44339268/pepsico-reportedly-in-talks-to-acquire-poppi-amid-rising-demand-for-probiotic-drinks" target="_blank" rel="noreferrer noopener">PepsiCo Reportedly In Talks To Acquire Poppi Amid Rising Demand For Probiotic Drinks</a></li>
</ul>

Market-Moving Exclusives

Exclusives

MGRM

EXCLUSIVE: FDA Approves Monogram Technologies' mBôs TKA System For Knee Surgery

EXCLUSIVE: Monogram Technologies Tells Benzinga 'The Company is Preparing for Commercialization and Evaluating Strategies to Support the Adoption of its Robotic-Assisted Technology'

EXCLUSIVE: Monogram Technologies Tells Benzinga Co. Announces FDA 510(k) Clearance For The Monogram mBôs TKA System

HC Wainwright &amp; Co. analyst Scott Buck maintains Veritone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) with a Buy and maintains $6 price target.

HC Wainwright & Co. Maintains Buy on Veritone, Maintains $6 Price Target

Capital One Financial February Credit Card Domestic 30+ Day Performing Delinquencies Rate 4.52%, Net Charge-Offs Rate 6.35% - Filing

Ascendiant Capital analyst Edward Woo maintains Daxor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXR#NASDAQ">DXR</a>) with a Buy and raises the price target from $24.75 to $25.

Ascendiant Capital Maintains Buy on Daxor, Raises Price Target to $25

Ascendiant Capital analyst Edward Woo maintains Aemetis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMTX#NASDAQ">AMTX</a>) with a Buy and raises the price target from $18 to $19.

AMTX

Ascendiant Capital Maintains Buy on Aemetis, Raises Price Target to $19

Press Releases

Excellos Selected as Decentralized Manufacturing Unit to Support Galapagos' CAR-T Cell Therapy Clinical Study Close to Cancer Treatment Centers in the San Diego Area

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Comments

Galapagos

ニュース

パートナーシップ

ベンジンガ・グローバル